Drug intelligence / Profile preview

D797

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical

Overview

D797 is a drug developed by Chong Kun Dang, which has been investigated in clinical trials. It is often studied in combination with Memantine HCl (referred to as D324 in some contexts) as part of the CKD-355 formulation. Clinical studies have evaluated its pharmacokinetic interactions, safety, and tolerability in healthy volunteers, as well as in the context of Central Nervous System Diseases and Alzheimer's Disease. The specific mechanism of action for D797 has not been detailed in the available information.

Beyond the preview

Go deeper on D797.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D797.

Explore the full profile